Regeneron Pharmaceuticals REGN Unveils C5 Complement Pipeline Strategy But Execution Risks Cap NearTerm Upside ELUT Elutia delivers blowout Q4 2025 EPS results yet shares fall 183 in postearnings trading DSXB Diana Pref B discloses no quarterly earnings figures and records no reported stock reaction in trading today